The EML4-ALK fusion gene is a potent driver oncogene found in a subset of NSCLC patients (typically young, never/light smokers). It serves as a predictive biomarker, indicating that the tumor is highly likely to respond to ALK tyrosine kinase inhibitors such as crizotinib, ceritinib, or alectinib, which target the aberrant ALK kinase activity.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Joseph Soko – 101 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies